The Prevalence of Mild Cognitive Impairment in China: Evidence from a Meta-Analysis and Systematic Review of 393,525 Adults.

IF 3.2 3区医学 Q2 CLINICAL NEUROLOGY Neuroepidemiology Pub Date : 2024-06-13 DOI:10.1159/000539802

Weiwei Wu, Guancheng Chen, Xiaohan Ren, Yuanyuan Zhao, Zhengmiao Yu, Haojun Peng, Chuxin Deng, Wenxin Song

{"title":"The Prevalence of Mild Cognitive Impairment in China: Evidence from a Meta-Analysis and Systematic Review of 393,525 Adults.","authors":"Weiwei Wu, Guancheng Chen, Xiaohan Ren, Yuanyuan Zhao, Zhengmiao Yu, Haojun Peng, Chuxin Deng, Wenxin Song","doi":"10.1159/000539802","DOIUrl":null,"url":null,"abstract":"Objective: This study aims to precisely determine the prevalence of mild cognitive impairment (MCI) in China, acknowledging its significance as a preclinical stage of dementia and a potential \"intervention window.\" The acceleration of the aging process in China underscores the urgency of this research.Methods: A comprehensive search was conducted across PubMed, Embase, Web of Science, CNKI, WFD, VIP, and CBM databases from their inception until March 1, 2023. The Agency for Healthcare Research and Quality (AHRQ) methodology checklist guided our quality assessment. A random-effects model meta-analysis was employed to synthesize the pooled prevalence data of MCI in China.Results: Our analysis encompassed 139 studies, incorporating data from 393,525 individuals aged 40 years and above. The studies were predominantly rated as moderate-to-high quality. The overall prevalence of MCI was determined to be 19.6% (95% CI: 17.7-21.6%). Subgroup analyses indicated variations in prevalence: 20.8% (95% CI: 18.9-22.7%) for P-MCI compared to 16.2% (95% CI: 11.7-20.7%) for DSM criteria. Geographically, prevalence in Southern China (21.0%, 95% CI: 18.1-23.9%) exceeded that in Northern China (17.6%, 95% CI: 15.9-19.4%). Notably, prevalence in hospitals (61.7%, 95% CI: 27.8-95.7%) was significantly higher than in nursing homes (16.1%, 95% CI: 14.3-17.9%) and communities (25.3%, 95% CI: 17.4-33.2%), especially after the COVID-19 outbreak.Conclusion: The study confirms a 19.6% prevalence rate of MCI in China, influenced by factors such as sample sources, beginning year of survey, and regional differences. It highlights the need for targeted screening and resource allocation to subpopulations at risk, aiming to prevent the progression to dementia.","PeriodicalId":54730,"journal":{"name":"Neuroepidemiology","volume":" ","pages":"1-18"},"PeriodicalIF":3.2000,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroepidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000539802","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aims to precisely determine the prevalence of mild cognitive impairment (MCI) in China, acknowledging its significance as a preclinical stage of dementia and a potential "intervention window." The acceleration of the aging process in China underscores the urgency of this research.

Methods: A comprehensive search was conducted across PubMed, Embase, Web of Science, CNKI, WFD, VIP, and CBM databases from their inception until March 1, 2023. The Agency for Healthcare Research and Quality (AHRQ) methodology checklist guided our quality assessment. A random-effects model meta-analysis was employed to synthesize the pooled prevalence data of MCI in China.

Results: Our analysis encompassed 139 studies, incorporating data from 393,525 individuals aged 40 years and above. The studies were predominantly rated as moderate-to-high quality. The overall prevalence of MCI was determined to be 19.6% (95% CI: 17.7-21.6%). Subgroup analyses indicated variations in prevalence: 20.8% (95% CI: 18.9-22.7%) for P-MCI compared to 16.2% (95% CI: 11.7-20.7%) for DSM criteria. Geographically, prevalence in Southern China (21.0%, 95% CI: 18.1-23.9%) exceeded that in Northern China (17.6%, 95% CI: 15.9-19.4%). Notably, prevalence in hospitals (61.7%, 95% CI: 27.8-95.7%) was significantly higher than in nursing homes (16.1%, 95% CI: 14.3-17.9%) and communities (25.3%, 95% CI: 17.4-33.2%), especially after the COVID-19 outbreak.

Conclusion: The study confirms a 19.6% prevalence rate of MCI in China, influenced by factors such as sample sources, beginning year of survey, and regional differences. It highlights the need for targeted screening and resource allocation to subpopulations at risk, aiming to prevent the progression to dementia.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中国轻度认知障碍的患病率：对393525名成年人的荟萃分析和系统回顾所提供的证据。

研究目的轻度认知功能障碍（MCI）是痴呆症的临床前阶段，也是潜在的 "干预窗口"，本研究旨在准确测定轻度认知功能障碍在中国的患病率。中国老龄化进程的加速凸显了这项研究的紧迫性：方法：对 PubMed、Embase、Web of Science、CNKI、WFD、VIP 和 CBM 数据库从开始到 2023 年 3 月 1 日进行了全面检索。医疗保健研究与质量机构（AHRQ）的方法清单为我们的质量评估提供了指导。我们采用随机效应模型荟萃分析来综合中国MCI的汇总患病率数据：我们的分析包括 139 项研究，涉及 393,525 名 40 岁及以上人群的数据。这些研究主要被评为中高质量。MCI的总患病率为19.6%（95% CI：17.7%-21.6%）。分组分析表明患病率存在差异：P-MCI 为 20.8%（95% CI：18.9%-22.7%），而 DSM 标准为 16.2%（95% CI：11.7%-20.7%）。从地域上看，华南地区的患病率（21.0%，95% CI：18.1%-23.9%）高于华北地区（17.6%，95% CI：15.9%-19.4%）。值得注意的是，医院的发病率（61.7%，95% CI：27.8%-95.7%）明显高于疗养院（16.1%，95% CI：14.3%-17.9%）和社区（25.3%，95% CI：17.4%-33.2%），尤其是在 COVID-19 爆发之后：该研究证实，受样本来源、调查起始年和地区差异等因素的影响，中国 MCI 患病率为 19.6%。研究强调，有必要对高风险亚人群进行有针对性的筛查和资源分配，以预防痴呆症的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neuroepidemiology 医学-公共卫生、环境卫生与职业卫生

CiteScore

9.90

自引率

1.80%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Neuroepidemiology'' is the only internationally recognised peer-reviewed periodical devoted to descriptive, analytical and experimental studies in the epidemiology of neurologic disease. The scope of the journal expands the boundaries of traditional clinical neurology by providing new insights regarding the etiology, determinants, distribution, management and prevention of diseases of the nervous system.